Results of carbon ion radiotherapy for skin carcinomas in 45 patients

Summary Background Heavy ions represent the best tool for external radiotherapy (RT) of inoperable tumours. Heavy ion RT has been used in the treatment of various tumours, especially for radioresistant tumours mediated by hypoxia, localized near organs at risk. Most of these treatments are concentr...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of dermatology (1951) Vol. 166; no. 5; pp. 1100 - 1106
Main Authors:	Zhang, H., Li, S., Wang, X.H., Li, Q., Wei, S.H., Gao, L.Y., Zhao, W.P., Hu, Z.G., Mao, R.S., Xu, H.S., Zhang, Q.N., Yue, Y.J., Tian, Z.Z., Ran, J.T., Xiao, G.Q., Zhan, W.L.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-05-2012 Wiley-Blackwell Oxford University Press
Subjects:	Adult Aged Aged, 80 and over Basal cell carcinoma Biological and medical sciences Carbon Carbon - therapeutic use Dermatology Disease Female Heavy Ions - therapeutic use Humans Hypoxia Kaplan-Meier Estimate Male Medical sciences Melanoma Middle Aged Patients Radiation therapy Radiotherapy - adverse effects Rectum Skin cancer Skin carcinoma Skin Neoplasms - radiotherapy Squamous cell carcinoma Toxicity Treatment Outcome Tumors Tumors of the skin and soft tissue. Premalignant lesions Human Skin disease Treatment Dermatology Malignant tumor Radiotherapy Cancer Skin cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Background Heavy ions represent the best tool for external radiotherapy (RT) of inoperable tumours. Heavy ion RT has been used in the treatment of various tumours, especially for radioresistant tumours mediated by hypoxia, localized near organs at risk. Most of these treatments are concentrated in deep‐seated tumours such as those of the brain, head, lung, liver, rectum and urogenital organs, and treatment of skin carcinomas is limited. Objectives To evaluate the outcome and toxicity after carbon ion RT for skin carcinomas at the Heavy Ion Research Facility in Lanzhou, China. Methods Between November 2006 and March 2009, 45 patients with skin carcinoma [squamous cell carcinoma (SCC) (n = 16), basal cell carcinoma (BCC) (n = 12), malignant melanoma (MM) (n = 7), Bowen disease (n = 8) and Paget disease (n = 2)] were treated with carbon ion RT within a clinical Phase I trial. Patients received total doses of 60–70 GyE for SCC and BCC, 61–75 GyE for MM, 60 GyE for Bowen disease and 42·5 GyE for Paget disease, administered in 6–11 fractions over 6–11 days, with a fraction dose of 7–10 GyE. Results The mean follow‐up was 24 months, range 12–36 months. The actuarial local control rates at 1 and 3 years were 90·9% and 65·5% for SCC, 91·7% and 80·2% for BCC, 85·7% and 42·9% for MM, 90% and 90% for Bowen and Paget diseases, respectively. The actuarial 1‐ and 3‐year overall survival rates for 45 patients were 88·9% and 86%, respectively. No severe side‐effects greater than Common Toxicity Criteria grade 3 have been observed. Conclusions The results demonstrated that heavy ion RT offers high local tumour control and progression‐free survival rates without significant radiation‐induced toxicity for patients with skin carcinomas.
Bibliography:	ArticleID:BJD10764 istex:82CE3992403D971C7792F8C357577B6ECC64F7DB ark:/67375/WNG-RKV8BLWG-J Funding sources  No external funding. Conflicts of interest  None to declare.
ISSN:	0007-0963 1365-2133
DOI:	10.1111/j.1365-2133.2011.10764.x